Hatice Terzi

Dr. Hatice Terzi

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2022 in Turkish Journal of Hematology
Verified
Journal Article
Open access
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag
GSGuldane Cengiz Seval
Guldane Cengiz Seval
IYIpek Yonal-Hindilerden
Ipek Yonal-Hindilerden
FHFehmi Hindilerden
Fehmi Hindilerden
NANeslihan Andıç
Neslihan Andıç
GÖGüner Hayri Özsan
Güner Hayri Özsan
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.

1 December 2019 in Indian Journal of Medical Research
Verified
Journal Article
Open access
PDF file
HTHatice Terzi
Hatice Terzi
AAAhmet Altun
Ahmet Altun
MŞMehmet Şencan
Mehmet Şencan
Background & objectives: Statins are one of the most widely used drugs and have antilipidemic effects as well as antioxidant, anti-inflammatory, anti-angiogenic and anti-tumorigenic effects. It has been shown that the synergistic combinations of statins which can provide better clinical benefit in the treatment of cancer and if administered with other anticancer agents, may be an alternative treatment modality. The aim of this study was to assess the efficacy of administrating statin in multiple myeloma (MM) cell line on cell proliferation. Methods: U266 myeloma cells were cultured in 25 or 75 cm2 flasks by using cell culture medium mixtures obtained with the supplementation of 10 per cent foetal bovine serum and one per cent of penicillin-streptomycin into RPMI 1640 medium. When the cells reached confluence (reached to the density of 70%), they were reproduced by passaging. Cytotoxicity was evaluated by using the XTT test. Results: Statins (atorvastatin and simvastatin), were administered to the U266 myeloma cell line at 100, 50, 25, 12.5, 6.25 and 3.12 μM concentrations. Inhibitor concentration 50 (IC50) values calculated for atorvastatin and simvastatin were determined as 94 and 38 μM, respectively. While 100, 50, 25, 12.5, 6.25 and 3.12 μM concentrations were used for bortezomib, the IC50 value calculated for this agent was 18.2 nM. When six concentrations of bortezomib used in the study were combined with 12.5 μM inactive concentrations of statins that did not cause inhibition in cell proliferation, both atorvastatin and simvastatin increased the effect of bortezomib at all the concentrations used, and simvastatin showed a stronger efficacy than atorvastatin. Interpretation & conclusions: Our in vitro results indicated that atorvastatin and simvastatin when used along with the conventional treatment in myeloma patients, may improve the effectiveness of the standard therapy and prevent the bortezomib-induced cytotoxic and neurotoxic side effects when used at a low dose. Further studies need to be done in MM patints to confirm these findings.

15 May 2025 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
IKIbrahim Karaduman
Ibrahim Karaduman
HTHatice Terzi
Hatice Terzi
STSeyma Tastemur
Seyma Tastemur
MSMehmet Sencan
Mehmet Sencan
Background and Aim: Burkitt lymphoma is a highly aggressive type of B-cell non-Hodgkin lymphoma. While it is more commonly seen in children and adolescents, it ac-counts for about 1-2% of adult lymphomas. Since it has high Ki-67 ratios, both its progres-sion rate and sensitivity to chemotherapy are high. However, treatment success decreases in chemotherapy-resistant relapsed/refractory groups. Therefore, new and less toxic therapeutic agents targeting biological pathways related to Burkitt lymphoma pathogenesis are needed. In our study, we aimed to determine the antitumoral efficacy of PI3K/AKT/mTOR pathway inhibitor ETP 45658 and antioxidant Resveratrol, which play a role in Burkitt lymphoma pathogenesis on a Burkitt lymphoma cell line. Methods: Burkitt lymphoma Raji cell line was used in our study. ETP 45658 was applied to the cell line at concentrations of 50, 25, 12.5, 1, 0.1, and 0.01 µM, both alone and in combi-nation with 100 µM resveratrol. The cytotoxic effects of ETP 45658 and the combination treatment on Raji cells were then evaluated using an in vitro XTT cell viability test. IC50 value was calculated according to the results obtained in the XTT test. Based on the IC50 value, the apoptosis assay was studied using the flow cytometry method. Results: Our research showed that increasing doses of ETP 45658, individually and in com-bination, had a statistically significant cytotoxic effect on Burkitt lymphoma Raji cells. This cytotoxic effect was found to be higher in combination treatment. In apoptosis experiments with the calculated IC50 value, it induced apoptosis weakly. Conclusion: Our study showed that ETP 45668 alone and in combination with resveratrol has antitumoral activity on the Burkitt lymphoma cell line. PI3K/Akt/mTOR pathway in-hibitors may be an alternative treatment option in patients with relapsed/refractory Burkitt lymphoma. However, more preclinical and clinical studies are needed.

14 July 2017 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
AGAliihsan Gemici
Aliihsan Gemici
IAIsmet Aydogdu
Ismet Aydogdu
HTHatice Terzi
Hatice Terzi
MSMehmet Sencan
Mehmet Sencan
AAAlma Aslan
Alma Aslan
FAFevzi Altuntas
Fevzi Altuntas

30 March 2021 in National Journal of Health Sciences
Verified
Journal Article
Open access
OKOzge Kurtkulagi
Ozge Kurtkulagi
OYOzlem Yonem
Ozlem Yonem
HTHatice Terzi
Hatice Terzi
Objective: The underlying conditions/diseases of scattered white spots in the duodenum are rather not very clear in the literature. We aimed to find out whether Helicobacter pylori, diabetes mellitus or inflammation has an impact on the presence of duodenal white spots. Materials & Methods: We included all patients who underwent endoscopy between the time-period 2007-2017 in the Endoscopy Unit of Cumhuriyet University and had scattered white spots in the duodenum. Our control group was formed by randomly selected patients who underwent endoscopy at the same time period in whom duodenal biopsy was taken. The demographic data of both the patient and the control group, the presence of diabetes, endoscopic and histological diagnoses, neutrophil lymphocyte ratio, thrombocyte lymphocyte ratio, mean platelet volume and erythrocyte distribution width were obtained from the computer system of the hospital in detail. Results: Peptic ulcer disease was found to be significantly more prevalent in patients with white spots than the control group. We could not find any difference between the patient and control groups by means of either neutrophil lymphocyte ratio, platelet lymphocyte ratio, mean platelet volume and erythrocyte distribution width, Helicobacter pylori, positivity or presence of diabetes. Conclusion: Both diabetes mellitus and H. pylori are causes of systemic inflammation. In our study, we evaluated whether patients with white spots were associated with systemic inflammation by looking at popular inflammation markers. We could not find any difference between the two groups in terms of these markers. Keywords: White spots, Duodenum, Diabetes mellitus, Systemic inflammation, Lymphangiectasia, Giardiasis, Chronic nonspecific duonetitis.

1 August 2015 in Journal of Hematology and Blood Disorders
Verified
Journal Article
Open access
PDF file
HTHatice Terzi
Hatice Terzi
KSKorkmaz S
Korkmaz S
KOKaya Ob
Kaya Ob
KTKaçan T
Kaçan T
ŞMŞencan M
Şencan M
TUTurkey and Şencan M AFFILIATIONS Cumhuriyet University
Turkey and Şencan M AFFILIATIONS Cumhuriyet University
Multiple myeloma is a neoplastic disease characterized by neoplastic proliferation of plasma cells and monoclonal protein expression and related tissue damage.